Multiple Sclerosis:治療薬パイプラインレビュー(2014年上半期)

◆英語タイトル:Multiple Sclerosis - Pipeline Review, H1 2014
◆発行会社/調査会社:Global Markets Direct
◆商品コード:GMDHC4657IDB
◆発行日:2014年3月31日
◆調査対象地域:グローバル
◆ページ数:648
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD5,000 ⇒換算¥550,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD7,500 ⇒換算¥825,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[Multiple Sclerosis:治療薬パイプラインレビュー(2014年上半期)]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

Multiple Sclerosis – Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Multiple Sclerosis – Pipeline Review, H1 2014’, provides an overview of the Multiple Sclerosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Multiple Sclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Sclerosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Multiple Sclerosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Multiple Sclerosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Multiple Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Multiple Sclerosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Multiple Sclerosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Multiple Sclerosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

*** レポート目次(コンテンツ)***

Table of Contents
Table of Contents 2
Introduction 8
Multiple Sclerosis Overview 9
Therapeutics Development 10
Multiple Sclerosis – Therapeutics under Development by Companies 12
Multiple Sclerosis – Therapeutics under Investigation by Universities/Institutes 25
Multiple Sclerosis – Pipeline Products Glance 28
Multiple Sclerosis – Products under Development by Companies 32
Multiple Sclerosis – Products under Investigation by Universities/Institutes 45
Multiple Sclerosis – Companies Involved in Therapeutics Development 47
Multiple Sclerosis – Therapeutics Assessment 186
Drug Profiles 209
Multiple Sclerosis – Recent Pipeline Updates 519
Multiple Sclerosis – Dormant Projects 602
Multiple Sclerosis – Discontinued Products 612
Multiple Sclerosis – Product Development Milestones 613
Appendix 620

List of Tables
Number of Products under Development for Multiple Sclerosis, H1 2014 37
Number of Products under Development for Multiple Sclerosis - Comparative Analysis, H1 2014 38
Number of Products under Development by Companies, H1 2014 40
Number of Products under Development by Companies, H1 2014 (Contd..1) 41
Number of Products under Development by Companies, H1 2014 (Contd..2) 42
Number of Products under Development by Companies, H1 2014 (Contd..3) 43
Number of Products under Development by Companies, H1 2014 (Contd..4) 44
Number of Products under Development by Companies, H1 2014 (Contd..5) 45
Number of Products under Development by Companies, H1 2014 (Contd..6) 46
Number of Products under Development by Companies, H1 2014 (Contd..7) 47
Number of Products under Development by Companies, H1 2014 (Contd..8) 48
Number of Products under Development by Companies, H1 2014 (Contd..9) 49
Number of Products under Development by Companies, H1 2014 (Contd..10) 50
Number of Products under Development by Companies, H1 2014 (Contd..11) 51
Number of Products under Investigation by Universities/Institutes, H1 2014 53
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 54
Comparative Analysis by Late Stage Development, H1 2014 55
Comparative Analysis by Clinical Stage Development, H1 2014 56
Comparative Analysis by Early Stage Development, H1 2014 57
Comparative Analysis by Unknown Stage Development, H1 2014 58
Products under Development by Companies, H1 2014 59
Products under Development by Companies, H1 2014 (Contd..1) 60
Products under Development by Companies, H1 2014 (Contd..2) 61
Products under Development by Companies, H1 2014 (Contd..3) 62
Products under Development by Companies, H1 2014 (Contd..4) 63
Products under Development by Companies, H1 2014 (Contd..5) 64
Products under Development by Companies, H1 2014 (Contd..6) 65
Products under Development by Companies, H1 2014 (Contd..7) 66
Products under Development by Companies, H1 2014 (Contd..8) 67
Products under Development by Companies, H1 2014 (Contd..9) 68
Products under Development by Companies, H1 2014 (Contd..10) 69
Products under Development by Companies, H1 2014 (Contd..11) 70
Products under Development by Companies, H1 2014 (Contd..12) 71
Products under Investigation by Universities/Institutes, H1 2014 72
Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 73
Multiple Sclerosis - Pipeline by Biogen Idec Inc., H1 2014 74
Multiple Sclerosis - Pipeline by Amgen Inc., H1 2014 75
Multiple Sclerosis - Pipeline by Athersys, Inc., H1 2014 76
Multiple Sclerosis - Pipeline by GlaxoSmithKline plc, H1 2014 77
Multiple Sclerosis - Pipeline by MedImmune, LLC, H1 2014 78
Multiple Sclerosis - Pipeline by Biotest AG, H1 2014 79
Multiple Sclerosis - Pipeline by Alkermes Plc, H1 2014 80
Multiple Sclerosis - Pipeline by Merck & Co., Inc., H1 2014 81
Multiple Sclerosis - Pipeline by AbGenomics International, Inc., H1 2014 82
Multiple Sclerosis - Pipeline by Plexxikon Inc., H1 2014 83
Multiple Sclerosis - Pipeline by Apitope International NV, H1 2014 84
Multiple Sclerosis - Pipeline by Hanwha Chemical Corporation, H1 2014 85
Multiple Sclerosis - Pipeline by Aphios Corporation, H1 2014 86
Multiple Sclerosis - Pipeline by Acorda Therapeutics, Inc., H1 2014 87
Multiple Sclerosis - Pipeline by Biocon Limited, H1 2014 88
Multiple Sclerosis - Pipeline by Eisai Co., Ltd., H1 2014 89
Multiple Sclerosis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2014 90
Multiple Sclerosis - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2014 91
Multiple Sclerosis - Pipeline by Pfizer Inc., H1 2014 92
Multiple Sclerosis - Pipeline by Rigel Pharmaceuticals, Inc., H1 2014 93
Multiple Sclerosis - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2014 94
Multiple Sclerosis - Pipeline by Zydus Cadila Healthcare Limited, H1 2014 95
Multiple Sclerosis - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2014 96
Multiple Sclerosis - Pipeline by Exelixis, Inc., H1 2014 97
Multiple Sclerosis - Pipeline by Paratek Pharmaceuticals, Inc., H1 2014 98
Multiple Sclerosis - Pipeline by Celgene Corporation, H1 2014 99
Multiple Sclerosis - Pipeline by OPKO Health, Inc., H1 2014 100
Multiple Sclerosis - Pipeline by BrainStorm Cell Therapeutics Inc., H1 2014 101
Multiple Sclerosis - Pipeline by 4SC AG, H1 2014 102
Multiple Sclerosis - Pipeline by Addex Therapeutics, H1 2014 103
Multiple Sclerosis - Pipeline by Evotec AG, H1 2014 104
Multiple Sclerosis - Pipeline by Hemispherx Biopharma, Inc., H1 2014 105
Multiple Sclerosis - Pipeline by Harbor Therapeutics, Inc., H1 2014 106
Multiple Sclerosis - Pipeline by Neuralstem, Inc., H1 2014 107
Multiple Sclerosis - Pipeline by Antisense Therapeutics Limited, H1 2014 108
Multiple Sclerosis - Pipeline by Idera Pharmaceuticals, Inc., H1 2014 109
Multiple Sclerosis - Pipeline by Karo Bio AB, H1 2014 110
Multiple Sclerosis - Pipeline by Almirall, S.A., H1 2014 111
Multiple Sclerosis - Pipeline by Lpath, Inc., H1 2014 112
Multiple Sclerosis - Pipeline by Bionomics Limited, H1 2014 113
Multiple Sclerosis - Pipeline by MultiCell Technologies, Inc., H1 2014 114
Multiple Sclerosis - Pipeline by Catalyst Pharmaceutical Partners, Inc., H1 2014 115
Multiple Sclerosis - Pipeline by Nutra Pharma Corporation, H1 2014 116
Multiple Sclerosis - Pipeline by Compugen Ltd., H1 2014 117
Multiple Sclerosis - Pipeline by Critical Outcome Technologies Inc., H1 2014 118
Multiple Sclerosis - Pipeline by Acadia Pharmaceuticals Inc., H1 2014 119
Multiple Sclerosis - Pipeline by Accentia Biopharmaceuticals, Inc., H1 2014 120
Multiple Sclerosis - Pipeline by Arena Pharmaceuticals, Inc., H1 2014 121
Multiple Sclerosis - Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2014 122
Multiple Sclerosis - Pipeline by ProMetic Life Sciences Inc., H1 2014 123
Multiple Sclerosis - Pipeline by Xenetic Biosciences plc, H1 2014 124
Multiple Sclerosis - Pipeline by HanAll Biopharma Co., Ltd., H1 2014 125
Multiple Sclerosis - Pipeline by Cytos Biotechnology AG, H1 2014 126
Multiple Sclerosis - Pipeline by LG Life Sciences, Ltd., H1 2014 127
Multiple Sclerosis - Pipeline by Pluristem Therapeutics Inc., H1 2014 128
Multiple Sclerosis - Pipeline by Resverlogix Corp., H1 2014 129
Multiple Sclerosis - Pipeline by Sareum Holdings plc, H1 2014 130
Multiple Sclerosis - Pipeline by Transgene Biotek Limited, H1 2014 131
Multiple Sclerosis - Pipeline by Shenzhen Beike Biotechnology Co., Ltd., H1 2014 132
Multiple Sclerosis - Pipeline by Morphotek, Inc., H1 2014 133
Multiple Sclerosis - Pipeline by Digna Biotech, S.L., H1 2014 134
Multiple Sclerosis - Pipeline by Antitope Ltd., H1 2014 135
Multiple Sclerosis - Pipeline by Axxam SpA, H1 2014 136
Multiple Sclerosis - Pipeline by Pieris AG, H1 2014 137
Multiple Sclerosis - Pipeline by Hutchison MediPharma Limited, H1 2014 138
Multiple Sclerosis - Pipeline by Trophos SA, H1 2014 139
Multiple Sclerosis - Pipeline by Argos Therapeutics, Inc., H1 2014 140
Multiple Sclerosis - Pipeline by Affectis Pharmaceuticals AG, H1 2014 141
Multiple Sclerosis - Pipeline by Coronado Biosciences, Inc., H1 2014 142
Multiple Sclerosis - Pipeline by MacroGenics, Inc., H1 2014 143
Multiple Sclerosis - Pipeline by Q Therapeutics, Inc., H1 2014 144
Multiple Sclerosis - Pipeline by Catabasis Pharmaceuticals, Inc., H1 2014 145
Multiple Sclerosis - Pipeline by Vaccinex, Inc., H1 2014 146
Multiple Sclerosis - Pipeline by Kineta, Inc., H1 2014 147
Multiple Sclerosis - Pipeline by MSM Protein Technologies, Inc., H1 2014 148
Multiple Sclerosis - Pipeline by Vascular Biogenics Ltd., H1 2014 149
Multiple Sclerosis - Pipeline by Endocyte, Inc., H1 2014 150
Multiple Sclerosis - Pipeline by Theraclone Sciences, Inc., H1 2014 151
Multiple Sclerosis - Pipeline by Effimune SAS, H1 2014 152
Multiple Sclerosis - Pipeline by Siena Biotech S.p.A., H1 2014 153
Multiple Sclerosis - Pipeline by Virogenomics, Inc., H1 2014 154
Multiple Sclerosis - Pipeline by Omeros Corporation, H1 2014 155
Multiple Sclerosis - Pipeline by Bolder Biotechnology, Inc., H1 2014 156
Multiple Sclerosis - Pipeline by Aegis Therapeutics, LLC, H1 2014 157
Multiple Sclerosis - Pipeline by Cellceutix Corporation, H1 2014 158
Multiple Sclerosis - Pipeline by Biovista Inc., H1 2014 159
Multiple Sclerosis - Pipeline by SanBio, Inc., H1 2014 160
Multiple Sclerosis - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2014 161
Multiple Sclerosis - Pipeline by Provid Pharmaceuticals, Inc., H1 2014 162
Multiple Sclerosis - Pipeline by Vitae Pharmaceuticals, Inc., H1 2014 163
Multiple Sclerosis - Pipeline by Biokine Therapeutics Ltd., H1 2014 164
Multiple Sclerosis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2014 165
Multiple Sclerosis - Pipeline by OncoImmune, Inc., H1 2014 166
Multiple Sclerosis - Pipeline by to-BBB technologies BV, H1 2014 167
Multiple Sclerosis - Pipeline by PharmaEssentia Corporation, H1 2014 168
Multiple Sclerosis - Pipeline by KAHR medical Ltd., H1 2014 169
Multiple Sclerosis - Pipeline by M's Science Corporation, H1 2014 170
Multiple Sclerosis - Pipeline by Phenomenome Discoveries, Inc., H1 2014 171
Multiple Sclerosis - Pipeline by Lycera Corp., H1 2014 172
Multiple Sclerosis - Pipeline by MAKScientific, LLC, H1 2014 173
Multiple Sclerosis - Pipeline by RhinoCyte, Inc., H1 2014 174
Multiple Sclerosis - Pipeline by Vakzine Projekt Management GmbH, H1 2014 175
Multiple Sclerosis - Pipeline by Pfenex Inc., H1 2014 176
Multiple Sclerosis - Pipeline by Vicore Pharma AB, H1 2014 177
Multiple Sclerosis - Pipeline by Cellmid Limited, H1 2014 178
Multiple Sclerosis - Pipeline by Varinel, Inc., H1 2014 179
Multiple Sclerosis - Pipeline by Cognosci, Inc., H1 2014 180
Multiple Sclerosis - Pipeline by Immune Technologies and Medicine GmbH, H1 2014 181
Multiple Sclerosis - Pipeline by Targazyme, Inc., H1 2014 182
Multiple Sclerosis - Pipeline by Nectid, Inc., H1 2014 183
Multiple Sclerosis - Pipeline by ProNoxis AB, H1 2014 184
Multiple Sclerosis - Pipeline by Nuron Biotech, Inc., H1 2014 185
Multiple Sclerosis - Pipeline by Cell Cure Neurosciences, Ltd., H1 2014 186
Multiple Sclerosis - Pipeline by GeNeuro SA, H1 2014 187
Multiple Sclerosis - Pipeline by VivaCell Biotechnology Espana S.L., H1 2014 188
Multiple Sclerosis - Pipeline by Forward Pharma A/S, H1 2014 189
Multiple Sclerosis - Pipeline by Genervon Biopharmaceuticals, LLC, H1 2014 190
Multiple Sclerosis - Pipeline by Regenesance BV, H1 2014 191
Multiple Sclerosis - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2014 192
Multiple Sclerosis - Pipeline by BRAINco Biopharma, S.L., H1 2014 193
Multiple Sclerosis - Pipeline by SOM Biotech SL, H1 2014 194
Multiple Sclerosis - Pipeline by Immune Response BioPharma, Inc., H1 2014 195
Multiple Sclerosis - Pipeline by Bionure Farma, S.L., H1 2014 196
Multiple Sclerosis - Pipeline by IntelliCell BioSciences Inc., H1 2014 197
Multiple Sclerosis - Pipeline by International Biotechnology Center Generium, H1 2014 198
Multiple Sclerosis - Pipeline by Visionary Pharmaceuticals, Inc., H1 2014 199
Multiple Sclerosis - Pipeline by Arrien Pharmaceuticals, LLC, H1 2014 200
Multiple Sclerosis - Pipeline by CalAsia Pharmaceuticals, Inc., H1 2014 201
Multiple Sclerosis - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2014 202
Multiple Sclerosis - Pipeline by Sage Therapeutics, H1 2014 203
Multiple Sclerosis - Pipeline by Lanthio Pharma B.V., H1 2014 204
Multiple Sclerosis - Pipeline by ReveraGen BioPharma, Inc., H1 2014 205
Multiple Sclerosis - Pipeline by Biomar Microbial Technologies, H1 2014 206
Multiple Sclerosis - Pipeline by ImmuNext, Inc., H1 2014 207
Multiple Sclerosis - Pipeline by Toleranzia AB, H1 2014 208
Multiple Sclerosis - Pipeline by XL-protein GmbH, H1 2014 209
Multiple Sclerosis - Pipeline by Glialogix, Inc., H1 2014 210
Multiple Sclerosis - Pipeline by Bionature E.A. Ltd., H1 2014 211
Multiple Sclerosis - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2014 212
Assessment by Monotherapy Products, H1 2014 213
Assessment by Combination Products, H1 2014 214
Number of Products by Stage and Target, H1 2014 217
Number of Products by Stage and Mechanism of Action, H1 2014 224
Number of Products by Stage and Route of Administration, H1 2014 232
Number of Products by Stage and Molecule Type, H1 2014 235
Multiple Sclerosis Therapeutics - Recent Pipeline Updates, H1 2014 546
Multiple Sclerosis - Dormant Projects, H1 2014 629
Multiple Sclerosis - Dormant Projects (Contd..1), H1 2014 630
Multiple Sclerosis - Dormant Projects (Contd..2), H1 2014 631
Multiple Sclerosis - Dormant Projects (Contd..3), H1 2014 632
Multiple Sclerosis - Dormant Projects (Contd..4), H1 2014 633
Multiple Sclerosis - Dormant Projects (Contd..5), H1 2014 634
Multiple Sclerosis - Dormant Projects (Contd..6), H1 2014 635
Multiple Sclerosis - Dormant Projects (Contd..7), H1 2014 636
Multiple Sclerosis - Dormant Projects (Contd..8), H1 2014 637
Multiple Sclerosis - Dormant Projects (Contd..9), H1 2014 638
Multiple Sclerosis - Discontinued Products, H1 2014 639

List of Figures
Number of Products under Development for Multiple Sclerosis, H1 2014 37
Number of Products under Development for Multiple Sclerosis - Comparative Analysis, H1 2014 38
Number of Products under Development by Companies, H1 2014 39
Number of Products under Investigation by Universities/Institutes, H1 2014 52
Comparative Analysis by Late Stage Development, H1 2014 55
Comparative Analysis by Clinical Stage Development, H1 2014 56
Comparative Analysis by Early Stage Products, H1 2014 57
Assessment by Monotherapy Products, H1 2014 213
Assessment by Combination Products, H1 2014 214
Number of Products by Top 10 Target, H1 2014 215
Number of Products by Stage and Top 10 Target, H1 2014 216
Number of Products by Top 10 Mechanism of Action, H1 2014 222
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 223
Number of Products by Top 10 Route of Administration, H1 2014 230
Number of Products by Stage and Top 10 Route of Administration, H1 2014 231
Number of Products by Top 10 Molecule Type, H1 2014 233
Number of Products by Stage and Top 10 Molecule Type, H1 2014 234

*** 掲載企業 ***

Biogen Idec Inc.
Amgen Inc.
Athersys, Inc.
GlaxoSmithKline plc
MedImmune, LLC
Biotest AG
Alkermes Plc
Merck & Co., Inc.
AbGenomics International, Inc.
Plexxikon Inc.
Apitope International NV
Hanwha Chemical Corporation
Aphios Corporation
Acorda Therapeutics, Inc.
Biocon Limited
Eisai Co., Ltd.
Mitsubishi Tanabe Pharma Corporation
Ono Pharmaceutical Co., Ltd.
Pfizer Inc.
Rigel Pharmaceuticals, Inc.
Vertex Pharmaceuticals Incorporated
Zydus Cadila Healthcare Limited
Hadasit Medical Research Services & Development Ltd
Exelixis, Inc.
Paratek Pharmaceuticals, Inc.
Celgene Corporation
OPKO Health, Inc.
BrainStorm Cell Therapeutics Inc.
4SC AG
Addex Therapeutics
Evotec AG
Hemispherx Biopharma, Inc.
Harbor Therapeutics, Inc.
Neuralstem, Inc.
Antisense Therapeutics Limited
Idera Pharmaceuticals, Inc.
Karo Bio AB
Almirall, S.A.
Lpath, Inc.
Bionomics Limited
MultiCell Technologies, Inc.
Catalyst Pharmaceutical Partners, Inc.
Nutra Pharma Corporation
Compugen Ltd.
Critical Outcome Technologies Inc.
Acadia Pharmaceuticals Inc.
Accentia Biopharmaceuticals, Inc.
Arena Pharmaceuticals, Inc.
RegeneRx Biopharmaceuticals, Inc.
ProMetic Life Sciences Inc.
Xenetic Biosciences plc
HanAll Biopharma Co., Ltd.
Cytos Biotechnology AG
LG Life Sciences, Ltd.
Pluristem Therapeutics Inc.
Resverlogix Corp.
Sareum Holdings plc
Transgene Biotek Limited
Shenzhen Beike Biotechnology Co., Ltd.
Morphotek, Inc.
Digna Biotech, S.L.
Antitope Ltd.
Axxam SpA
Pieris AG
Hutchison MediPharma Limited
Trophos SA
Argos Therapeutics, Inc.
Affectis Pharmaceuticals AG
Coronado Biosciences, Inc.
MacroGenics, Inc.
Q Therapeutics, Inc.
Catabasis Pharmaceuticals, Inc.
Vaccinex, Inc.
Kineta, Inc.
MSM Protein Technologies, Inc.
Vascular Biogenics Ltd.
Endocyte, Inc.
Theraclone Sciences, Inc.
Effimune SAS
Siena Biotech S.p.A.
Virogenomics, Inc.
Omeros Corporation
Bolder Biotechnology, Inc.
Aegis Therapeutics, LLC
Cellceutix Corporation
Biovista Inc.
SanBio, Inc.
KaloBios Pharmaceuticals, Inc.
Provid Pharmaceuticals, Inc.
Vitae Pharmaceuticals, Inc.
Biokine Therapeutics Ltd.
Kyorin Pharmaceutical Co., Ltd.
OncoImmune, Inc.
to-BBB technologies BV
PharmaEssentia Corporation
KAHR medical Ltd.
M's Science Corporation
Phenomenome Discoveries, Inc.
Lycera Corp.
MAKScientific, LLC
RhinoCyte, Inc.
Vakzine Projekt Management GmbH
Pfenex Inc.
Vicore Pharma AB
Cellmid Limited
Varinel, Inc.
Cognosci, Inc.
Immune Technologies and Medicine GmbH
Targazyme, Inc.
Nectid, Inc.
ProNoxis AB
Nuron Biotech, Inc.
Cell Cure Neurosciences, Ltd.
GeNeuro SA
VivaCell Biotechnology Espana S.L.
Forward Pharma A/S
Genervon Biopharmaceuticals, LLC
Regenesance BV
Inbiopro Solutions Pvt. Ltd.
BRAINco Biopharma, S.L.
SOM Biotech SL
Immune Response BioPharma, Inc.
Bionure Farma, S.L.
IntelliCell BioSciences Inc.
International Biotechnology Center Generium
Visionary Pharmaceuticals, Inc.
Arrien Pharmaceuticals, LLC
CalAsia Pharmaceuticals, Inc.
SK Biopharmaceuticals Co., Ltd.
Sage Therapeutics
Lanthio Pharma B.V.
ReveraGen BioPharma, Inc.
Biomar Microbial Technologies
ImmuNext, Inc.
Toleranzia AB
XL-protein GmbH
Glialogix, Inc.
Bionature E.A. Ltd.
Dong-A Socio Holdings Co Ltd

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(GMDHC4657IDB )"Multiple Sclerosis:治療薬パイプラインレビュー(2014年上半期)" (英文:Multiple Sclerosis - Pipeline Review, H1 2014)はGlobal Markets Direct社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。